IAP inhibitor, Embelin increases VCAM-1 levels on the endothelium, producing lymphocytic infiltration and antitumor immunity

Kosei Nakajima, Yoshinori Ino, Rie Yamazaki-Itoh, Chie Naito, Mari Shimasaki, Mami Takahashi, Minoru Esaki, Satoshi Nara, Yoji Kishi, Kazuaki Shimada, and Nobuyoshi Hiraoka

Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan; Department of Analytical Pathology, National Cancer Center Research Institute, Tokyo, Japan; Central Animal Division, National Cancer Center Research Institute, Tokyo, Japan; Hepato-Biliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo, Japan; Division of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo, Japan

ABSTRACT
There is an increasing unmet need for successful immunotherapeutic interventions. Lymphocyte extravasation via tumor tissue endothelial cells (TECs) is required for lymphocyte infiltration into tumor sites. This study aimed to investigate the clinical significance of dysfunctional TECs in pancreatic ductal adenocarcinoma (PDAC) and identify chemical compounds that boost tumor-infiltrating lymphocyte (TIL) numbers. We performed immunohistochemical detection and clinicopathological analysis of VCAM-1 on TECs, which is essential for lymphocyte trafficking. We characterized the gene expression profiles of TECs from fresh PDAC tissues. We isolated compounds that upregulated VCAM-1 and E-selectin expression in TECs and examined their biological activities. Compared to endothelial cells from chronic pancreatitis tissue, TECs showed significantly lower VCAM-1 and E-selectin expression and significant weaknesses in lymphocyte adhesion and transmigration, resulting in decreased T cell infiltration around vessels. Patients with a relatively high percentage of VCAM-1+ vessels among all vessels in PDAC tissue had an improved prognosis. A bioinformatics survey demonstrated that TNFR1 signaling was involved in abnormal VCAM-1 and E-selectin expression in TECs. We screened compounds affecting TNFR1 signaling, and the IAP inhibitor, Embelin, induced these molecules on TECs and enhanced T cell adhesion to TECs and transmigration. Furthermore, in vivo, Embelin enhanced tumor-infiltrating T cell numbers, leading to an antitumor immune response. Embelin accelerates TIL infiltration and the antitumor immune response by recovering VCAM-1 expression in TECs. Our strategy may be a therapeutic approach for accelerating the immunotherapeutic response in immune-quiescent tumors, leading to clinical trials’ success.

Introduction

Multiple mechanisms contribute to the heterogeneity of the immune response in the tumor microenvironment, leading to resistance to treatments. The immunological statuses of the tumor microenvironment can be largely classified into two categories: the immune-active ‘hot’ tumor status and immune-quiescent ‘cold’ tumor status. By this classification, pancreatic ductal adenocarcinoma (PDAC) has been reported to be a typical immune-quiescent tumor, and the efficacy of immunotherapies has been limited.

To characterize the treatment-resistant immune microenvironment of PDAC, we performed two large-scale cohort studies in which elevated levels of tumor-infiltrating lymphocytes (TILs) and the formation of intratumoral lymphoid organs were significantly associated with prolonged survival. Based on these results and considering that the cancer vasculature acts as an immune gatekeeper in neoplastic tissue, we next focused on the endothelial cells in the tumor tissue (TECs). Through the endothelium, lymphocytes access and infiltrate into tumor tissues to generate a successful cellular immune response. Nevertheless, TECs possess a distinct resistance to effector lymphocyte infiltration. It has been reported that TECs express molecules that accelerate and select for regulatory T cell extravasation and infiltration into tumor tissues. Additionally, TECs aberrantly express lymphocyte adhesion/homing-associated molecules, leading to abrogated immune recognition of tumor cells. Here, it was hypothesized that the pharmacological reprogramming of TECs might induce therapeutic T cell infiltration and produce a dynamic change in the tumor immune microenvironment.

For the first time in this study, we showed an integrated compound repositioning approach to enhance lymphocyte infiltration and identify possible agents to produce a beneficial immune response.

Materials and methods

Patients and samples

This study was approved by the Institutional Review Board of the National Cancer Center, Japan. Informed consent was obtained from all the participants involved in the study, and
all clinical investigations were conducted in line with the principles of the Declaration of Helsinki. Clinical and pathological data and the specimens used for immunohistochemical analysis were obtained through a detailed retrospective review of the medical records of 104 patients with PDAC: 104 patients who had undergone surgical resection between 2006 and 2008 at the National Cancer Center Hospital, Tokyo, and had available fresh-frozen tissues from surgically resected specimens were included in the study. None of the patients had received any therapy before surgery. All patients included in this study underwent macroscopic curative resection, and all cases involved conventional ductal carcinomas. The clinicopathological characteristics of the patients are summarized in Table 1. The median follow-up period after surgery for the patients as a whole and that for the living patients were 21.1 (3.6–109.2) and 39.85 (5.4–109.2) months, respectively. Each patient received follow-up care in the outpatient clinic every one to three months during the first postoperative year and every six to twelve months thereafter. Unless there was confirmation of disease relapse, the patients underwent physical examination, laboratory tests, chest radiography, abdominal computed tomography, and/or ultrasonography. The levels of the tumor markers carcinoembryonic antigen and carbohydrate antigen 19–9 were also measured until relapse. Recurrence was suspected when a new local or distant metastatic lesion was found on serial images and an increase in tumor marker levels was recognized. When disease progression was confirmed by repeated imaging studies, the date of the first suspicious radiological finding was used as the date of initial disease recurrence. At the census date (September 2017), we checked whether the patients were dead or alive; 27 patients (26.0%) were alive, 72 (69.2%) had died of pancreatic cancer, and 5 (4.8%) had died of other causes. All M1 (based on TNM classification13) patients had nodal metastasis around the abdominal aorta without any other form of metastasis.

### Table 1. Relationship between clinicopathological characteristics and the ratio of vessels composed of VCAM-1 expressing endothelial cells in total vessels (% VCAM1^+^V) in pancreatic ductal adenocarcinoma tissues (n = 104).

| Characteristic              | Total | High | Low | P     |
|----------------------------|-------|------|-----|-------|
| Age, years                 |       |      |     |       |
| <65                        | 54    | 31   | 23  | 0.169 |
| ≥65                        | 50    | 21   | 29  |       |
| Sex                        |       |      |     |       |
| Male                       | 64    | 29   | 35  |       |
| Female                     | 40    | 23   | 17  | 0.314 |
| Pathologic tumor status    |       |      |     |       |
| T1, T2                     | 61    | 34   | 27  |       |
| T3, T4                     | 43    | 18   | 25  | 0.232 |
| Pathologic node status     |       |      |     |       |
| N0                         | 24    | 14   | 10  |       |
| N1, N2                     | 80    | 38   | 42  | 0.486 |
| Pathologic metastasis status|     |      |     |       |
| M0                         | 89    | 45   | 44  |       |
| M1                         | 15    | 7    | 8   | 1.00  |
| Tumor histological grade   |       |      |     |       |
| G1                         | 14    | 10   | 4   |       |
| G2, G3                     | 90    | 42   | 48  | 0.149 |
| Tumor margin status        |       |      |     |       |
| Negative                   | 50    | 28   | 22  |       |
| Positive                   | 54    | 24   | 30  | 0.327 |
| Nerve plexus invasion*     |       |      |     |       |
| Absence                    | 21    | 17   | 4   |       |
| Presence                   | 83    | 35   | 48  | 0.003 |
| Lymphatic invasion*        |       |      |     |       |
| 0, 1                       | 27    | 14   | 13  | 1.00  |
| 2, 3                       | 77    | 38   | 39  |       |
| Venous invasion*           |       |      |     |       |
| 0, 1                       | 24    | 15   | 9   | 1.00  |
| 2, 3                       | 80    | 37   | 43  | 0.244 |
| Intrapancreatic neural invasion* | | | | |
| 0, 1                       | 31    | 21   | 10  | 0.031 |
| 2, 3                       | 73    | 31   | 42  |       |
| Adjuvant chemotherapy      |       |      |     |       |
| Presence                   | 20    | 9    | 11  | 0.804 |
| Absence                    | 84    | 43   | 41  |       |
| Total                      | 52    | 52   |     |       |

*: Classified according to the classification of pancreatic carcinoma of Japan Pancreas Society.

Bold letters: significant difference.
10% FBS, 1% penicillin-streptomycin-glutamine, and ECGS according to the manufacturer’s instructions.

Microarray analysis

Microarray analyses were carried out as described previously. Briefly, total RNA was extracted from TECs using an RNeasy-Mini kit (QIAGEN, Valencia, CA) and quantified using a NanoDrop 8000 instrument (Thermo Fisher Scientific, Waltham, MA). The RNA integrity number (RIN) was evaluated by a 2100 Bioanalyzer (Agilent, Santa Clara, CA). Cy3-labeled complementary RNA was prepared from total RNA and hybridized to the SurePrint G3 HumanGE8x60K-Microarray ver.2.0 (Agilent). The following analyses were performed at the Chemical Evaluation Research Institute (CERI, Tokyo, Japan). Briefly, signals were normalized by Gene Spring GX 14.5 (Agilent) with global normalization. To compare 2 groups of samples, i.e., endothelial cells derived from PDAC tissue samples and those derived from chronic pancreatitis (CP) tissue samples, Welch’s t-test was used for statistical significance. The statistically significant genes were classified into an upregulated gene expression group or a downregulated gene expression group. Then, the data were separately imported to Ingenuity Pathway Analysis (IPA) ver. 43605602 (QIAGEN), and canonical pathway analysis was performed by using the Core Analysis program.

Drug screening

A customized drug library targeting TNFR1 signaling was created, and the agents are summarized in Supplementary Table S1. Compounds were resolved in DMSO, and added to culture medium (final concentration, 0.05% DMSO). To eliminate cytotoxic compounds, normal pancreatic endothelial cells were seeded in a 96-well plate at $5 \times 10^3$ cells/well in ECM supplemented with 10% FBS and incubated at 37°C in a humidified atmosphere of 5% CO₂. The following day, the cells were treated with 10 μM compound targeting TNFR1 signaling, 10 ng/ml TNF-α (PeproTech, Rocky Hill, NJ) as positive control, or 0.05% DMSO as negative control for 48 hours. Cell survival was evaluated using the CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan). CCK-8 was added for 1 hour, and the absorbance at 450 nm was measured using a microplate reader. To perform qPCR-based drug screening, total RNA was extracted from endothelial cells in a 96-well cell culture plate by using Cells-to-CT 1-step TaqMan (Invitrogen/Thermo Scientific). Following the manufacturer’s protocols, qPCR was performed with QuantStudio3 (Thermo Scientific) and the following TaqMan gene expression assays: probe# Hs02786624_g1 for GAPDH, probe# Hs00174057_m1 for SELE, and probe# Hs01003372_m1 for VCAM1. CT values were normalized to the CT value of GAPDH, and the ΔΔCT method was used to compare the expression levels of the genes. To test drug effect, relative expression of genes is calculated based on the comparison with negative control as adding DMSO instead of compounds.

Effects of Embelin concentration on the expression of adhesion molecules

After cultivation of TECs in a 48-well plate supplemented with 0, 0.01, 0.1, 1.0, or 10.0 μM of Embelin (final concentration) for 48 hours, gene expression was measured quantitatively using qPCR methods as mentioned above.

Tumor transplantation experiments

Female C57/B6 mice, 4 to 6 weeks old, were purchased from Charles River Laboratories Japan (Kanagawa, Japan) and maintained in our facilities under standard conditions. KMPC9-A6 cells were established from a pancreatic cancer tumor formed in Ptf1αCre/+, LSL-K-RasG12D/+ mice (Ptf1αCre/+ mice were obtained from Mutant Mouse Regional Resource Centers, Bar Harbor, ME, and LSL-K-RasG12D/+ mice were obtained from the National Cancer Institute, Mouse Models of Human Cancers Consortium, Rockville, MD). KMPC9-A6 cells cultivated in RPMI-1640 supplemented with 5% FBS and 1% penicillin-streptomycin-glutamine (Invitrogen, Carlsbad, CA) at 37°C in a humidified incubator with 5% CO₂ were trypsinized, washed twice in PBS, and injected subcutaneously into the right hind flank of C57/B6 mice at a dose of 2 × 10⁶ cells/mouse in 100 μl of sterile PBS. Tumor size was measured with a digital caliper 2–3 times per week, and tumor volume was calculated according to the following formula: volume = length × width²/2. For antibody depletion, 0.2 mg of anti-CD8 antibody (53–6.72) or isotype immunoglobulin (BioCell, Irvine, CA) was injected intraperitoneally in 100 μl of PBS every 3 days during the course of experiments. Four microliters of Embelin [50 mg/ml in dimethyl sulfoxide (DMSO)] or DMSO diluted in 100 μl of PBS was injected intraperitoneally every 3 days during the course of experiments. Mice were sacrificed 30 days after transplantation, and the tumors were excised. Then, morphology, expression of VCAM-1 and ICAM-1 by endothelial cells, and tumor-infiltrating CD3⁺ T cells, CD8⁺ T cells, Foxp3⁺ regulatory T cells (Tregs), and Arg1⁺ M2 macrophages were analyzed by immunohistochemistry. The experiments were repeated three times. The animal experiments were conducted according to the guidelines of the Ethics Committee on Animal Experimentation and the Animal Welfare Regulations of the National Cancer Center.

Prior to the transplantation assays, we determined the concentration of Embelin that can kill the murine PDAC cell line KMPC9-A6 by MTT assay. MTT assay was performed using MTT cell count kit (Nacalai Tesque, Inc. Kyoto, Japan).

Accession number

The gene microarray data have been deposited and National Center for Biotechnology Information’s Gene Expression Omnibus data accession number is GSE151945.

Statistical analysis

Comparisons of qualitative variables were performed using Fisher’s exact test. Pairwise comparisons of subgroups were performed using the Mann-Whitney U test. Postoperative
overall survival (OS) and disease-free survival (DFS) rates were calculated by the Kaplan-Meier method. Univariate analysis was performed for prognostic factors using the log-rank test. The factors found to be significant by univariate analysis were subjected to multivariate analysis using the Cox proportional hazards model (the backward elimination method). For cell experiments, significant differences were determined by a two-sided t-test. Differences with \( P < .05 \) were considered statistically significant. Statistical analyses were performed with StatView 5.0 software (Abacus Concepts, Berkeley, CA).

The following subsections are included in “Supplementary Methods”: pathological examination, immunofluorescence, tube formation assay, immunohistochemistry, TUNEL assay, lymphocyte adhesion assay, lymphocyte transmigration assay, and measurement of Embelin concentration in blood of an animal tumor transplantation model.

Results

Endothelial cells in PDAC tissue are potentially dysfunctional for lymphocyte trafficking

The extravasation of lymphocytes through the endothelium is a multistep mechanism.\(^{15-17}\) Multiple molecular choices (i.e., available adhesion molecules and chemokines) at each step provide a large degree of combinational diversity, whereby different lymphocyte subsets can be recruited to appropriate sites. For the recruitment of effector T cells into cancer tissues, some adhesion molecules expressed on endothelial cells, including E-selectin, ICAM-1, and VCAM-1, are involved.\(^ {18}\) To determine whether endothelial cells are potentially dysfunctional for lymphocyte trafficking in PDAC tissue, we performed double immunohistochemistry to detect the expression of VCAM-1 in ERG1\(^+\) TECs (Figure 1a) using 104 samples of PDAC tissue and examined the infiltration of CD8\(^+\) T cells and their clinicopathological influences. The percentage of vessels composed of VCAM-1-expressing endothelial cells among all vessels (\%VCAM1\(^\text{V}\)) in the PDAC tissue samples was lower than that in chronic pancreatitis (CP) tissue samples (Figure 1b). Compared to those surrounding vessels lacking VCAM-1\(^-\) endothelial cells, tumor-infiltrating CD8\(^+\) T cells surrounding the vessels composed of VCAM-1\(^+\) endothelial cells were abundant in PDAC tissues (Figure 1c and Supplementary Figure S2); this was also observed in CP tissue. These results suggest that TECs are potentially dysfunctional for lymphocyte trafficking in PDAC tissue. Furthermore, Kaplan-Meier survival analysis revealed that PDAC patients with a higher \%VCAM1\(^\text{V}\) exhibited longer OS than those with a lower \%VCAM1\(^\text{V}\) (\( P = .029 \)) (Figure 1d). A similar tendency was found for DFS, although no statistically significant result was obtained (Figure 1e). When the variables significant by univariate Cox analysis were subjected to multivariate Cox analysis, increased lymphatic invasion and a reduced \%VCAM1\(^\text{V}\) were closely associated with reduced OS (hazard ratio 1.871, 95% confidential interval 1.162–3.012, \( P = .010 \)) (Table 2). A decreased \%VCAM1\(^\text{V}\) was significantly correlated with increased intrapancreatic neural invasion and the presence of nerve plexus invasion among the various clinicopathological factors examined (Table 1).

The unusual phenotype of TECs from PDAC tissue samples

To investigate the characteristics of TECs, we isolated CD31\(^+\)CD45\^- cells from fresh PDAC tissue samples. Morphologically, these cells showed a cobblestone-like appearance under confluent cell conditions with a large cytoplasm and small nucleus, and TECs composed \( > 95\% \) of all nucleated cells (Supplementary Figure S3A). Endothelial cell markers, CD31 and ERG1, were intensely expressed in these cells (Supplementary Figure S3B), consistent with the pathological findings (Supplementary Figure S1). Next, to examine the cellular phenotype of the CD31 and ERG1 double-positive cells, a tube formation assay was performed, and angiogenic potential was analyzed in TECs compared with endothelial cells isolated from a normal pancreas. TECs had the angiogenic ability (Supplementary Figure S3C). Automatic image analysis showed that compared to normal pancreatic endothelial cells, TECs tended to form short vessels, a narrow capillary network area, and increased numbers/lengths of isolated branches, indicating that the TECs had some different angiogenic characteristics than the endothelial cells from normal pancreas tissue (Supplementary Figures S3D and S3E).

To evaluate the function of TECs in lymphocyte trafficking, we examined the adherence of lymphocytes to TECs and the transmigration of lymphocytes through a TEC monolayer. An adhesion assay showed that lymphocytes adhered significantly less to TECs than normal pancreatic endothelial cells (Figure 1f). A transmigration assay also showed that TECs exhibited weaker supporting activities in lymphocyte transmigration than normal pancreatic endothelial cells (Figure 1g). These results implied that the TECs had dysfunctional characteristics for lymphocyte trafficking.

Delineating a signaling shift in the TNFR1 pathway in TECs

To find a molecular target for compound identification to enhance lymphocyte trafficking, we needed to clarify what molecules and pathways were distinct between TECs and endothelial cells from CP tissue. The gene expression profiles of endothelial cells from PDAC and CP tissue samples were analyzed using a microarray technique and compared. Scatter plot analysis graphed the gene expression of the two different cell types. In total, 2,748 genes exhibited significantly different expression between the two cell types (Figure 2a). Next, we employed bioinformatics software, termed Ingenuity Pathway Analysis (IPA), and visualized the pathways of interest. The analysis identified and ranked the distinct signaling pathways between TECs and endothelial cells from CP tissue, and 47 pathways were identified (\( P < .05 \)): 31 pathways were downregulated, and 16 pathways were upregulated (Figure 2b, Supplementary Table S2, and Supplementary Figure S4A).

We found downregulation of several genes in the TNFR1 signaling pathway encoding major molecules involved in lymphocyte trafficking\(^ {19} \) (Figure 2c), and we focused on TNFR1 signaling, which ranked second among the 31 downregulated pathways (Figure 2b). Since TNFR1 is involved in a variety of cellular responses based on cellular origins,\(^ {20} \) it was important to integrate the general information in the IPA database and...
the current understanding of TNFR signaling in endothelial cells\textsuperscript{19} to delineate an underlying interaction (Figure 2c).

To determine the protein status of downstream molecules in the TNFR1 signaling pathway in TECs from PDAC tissue, we detected the expression levels of E-selectin, VCAM-1, and ICAM-1 (Supplementary Figure S1E). The ratios of designated molecule-expressing vessels to all vessels were then calculated. Box plots showed that E-selectin and VCAM-1 expression was reduced in most TECs compared to that in CP (Figure 2d), implying insufficient activation of TNFR1 signaling in the TECs. This finding also implied that the downregulation of E-selectin or VCAM-1 expression might be responsible for the reduced adherence and transmigration characteristics of TECs and that E-selectin and VCAM-1 could be therapeutic targets.
to enhance lymphocyte adhesion. Meanwhile, ICAM-1 was expressed in most TECs, although its staining intensity was often weaker than that in CP (Supplementary Figure S5). It is possible that ICAM-1 gene expression levels might be reduced in TECs.

The gene expression profiles also showed that FADD, MADD, proCASP8, CASP8, and CASP2, which are apoptosis-associated molecules, exhibited upregulated expression in TECs (Figure 2c and Supplementary Figure S6), although few apoptotic endothelial cells were found in PDAC tissues (data not shown). This finding might imply a signaling shift in the TNFR1 pathway in the TECs but does not accelerate endothelial cell apoptosis.

**Compound screening for candidates targeting TNFR1 signaling to enhance immune cell infiltration**

Based on the results shown above, we planned a drug screen to identify a compound that boosts lymphocyte infiltration (Supplementary Figure S4B). As a first step, we recruited various compounds, inhibitors, and activators targeting TNFR1 signaling and created a customized drug library (Supplementary Table S1). Next, to exclude harmful compounds, a cytotoxicity test was performed, and the cutoff value was defined as >80% cell survival; consequently, 36 nontoxic agents were selected (Supplementary Figure S4C). To further identify E-selectin- or VCAM1-inducing compounds, qPCR-based screening was performed. Since different endothelial signaling pathways may be activated under conflu ent cellular conditions versus sparse conditions due to cell-to-cell interactions, we performed drug screening under these two experimental conditions to evaluate endothelial cell responses to the compounds. We also used mixed endothelial cells derived from three PDAC samples selected randomly to represent the average characteristics of TECs, since TECs are potentially heterogeneous. As expected, the results showed that different pharmacological reactions were observed. Overall, four drugs in group C, which are inhibitors of apoptosis protease (IAP) inhibitors, tended to upregulate VCAM-1 expression under both confluent and sparse conditions (Figure 3a). Therefore, the 4 IAP inhibitors – AZD5582, BV-6, Embelin, and LCL161, were evaluated in lymphocyte adhesion and transmigration assays. To mimic the clinical conditions of the immune microenvironment of PDAC, we further prepared TILs from patient surgical samples and used these cells in the cellular assays. Representative results revealed that the addition of AZD5582, BV-6, Embelin, or LCL161 largely increased the adhesion between the TILs and TECs and that Embelin significantly upregulated this interaction (Figure 3b). Also, Embelin significantly enhanced the transmigration of TILs (Figure 3c). Thus, our integrated compound screening study might have identified a possible agent to enhance lymphocyte infiltration to produce a beneficial immune response. Upon analyzing the relationship between the induction of adhesion molecules and the concentration of Embelin in TECs, Embelin concentration of more than 0.1 µM could effectively induce the expression of VCAM1 (Figure 3d) and SELE (Figure 3e) genes, with stronger expression at higher concentrations.

**Embelin facilitates T cell recruitment in murine PDAC tissue to induce an antitumor immune response**

Next, we examined whether Embelin treatment facilitates tumor-infiltrating T cells and induces an antitumor immune response in vivo. We injected the murine PDAC cell line KMPC9-A6, which was established from a PDAC tumor formed in an aged Ptf1aCre+; LSL-K-RasG12D/+ mouse, into the right hind flank of syngeneic C57BL/6 mice. Since IAPs inhibit apoptosis and their expression is elevated in many cancer cells, IAP inhibitors, including Embelin, induce cell death and have antitumor activity, as reported earlier. To avoid the direct tumor-cell killing effect of Embelin, we determined the Embelin concentration that could kill KMPC9-A6 cells in vitro, which was more than 3.13 µM (Supplementary Figure S4D). We set Embelin injection amounts and timing (Materials and Methods, and Supplementary Figure S7) because Embelin has tumor-killing activity, relatively rapid blood clearance, and effective induction of VCAM-1 and E-selectin at low concentrations (Figure 3d and e). Indeed, three hours after the intraperitoneal injection of Embelin, the Embelin blood concentration dropped below 3 µM and was kept within the effective concentration for more than 48 hours in this model (Supplementary Figure S4E). Tumor
growth was significantly delayed by Embelin treatment compared with no treatment (Figure 4a and b). Immunohistochemical and immunofluorescence analyses revealed that the %VCAM1" and %ICAM1" increased significantly in the Embelin-treated tumors compared with those in the untreated tumors (Figure 4c and d and Supplementary Figures S8A-S8D).

Additionally, significant CD3" and CD8" T cell infiltration was observed in the Embelin-treated tumors (Figure 4e and f, and Supplementary Figures S8E-S8H). In contrast, tumor-infiltrating immune-suppressive cells were reduced in the Embelin-treated tumors (Figure 4g and h): the ratio of tumor-infiltrating Foxp3" Treg/CD8" T cells was significantly lower and Arg1" M2 macrophage infiltration tended to be lower in the Embelin-treated tumors compared to untreated tumors.

Next, we investigated the effect of depleting CD8" T cells from animals on tumor growth. CD8" T cell depletion effectively blocked the tumor growth inhibition mediated by treatment with Embelin (Figure 4a). These findings suggested that Embelin efficiently induced T cell migration in vivo and promoted an antitumor responsive microenvironment, and that tumor growth was inhibited through an adaptive immune reaction.

**Discussion**

To date, various compound screening/repositioning methods have been reported to target malignant features of cancer, e.g., proliferation, motility, invasion, and metastasis. This study is
the first compound identification study showing boosted lymphocyte infiltration. So far, only limited blocking antibodies targeting TECs for acceleration and selection of T cell extravasation and infiltration have been reported.\(^9,10\) We identified a novel compound that induced T cell infiltration, leading to tumor shrinkage.

Lymphocytes cross the vascular endothelium by multiple steps consisting of tethering, rolling, arrest, crawling, and
In lymphocyte extravasation, underlying cooperative molecular participants expressed on the endothelium, including selectins, ICAMs, VCAM-1, VE-cadherin, CD31 (PECAM1), CD99, and JAMA, are involved. Endothelial cells are activated with the transcriptional induction of numerous leukocyte-trafficking molecules, termed type II activation, mostly driven by cytokines such as TNF-α and IL-1β. Among the adhesion molecules, E-selectin, ICAM-1, and VCAM-1 are induced in type II activation, which are downstream effector molecules of the TNFR1 pathway. In endothelial cells, TNFR1 signaling produces two distinct cellular events: cell apoptosis and lymphocyte extravasation support.

In contrast to the endothelial cells derived from CP, whose phenotype was similar to that of the endothelial cells with type II activation in this study, the phenotype of TECs was different and rather dysfunctional. In the TNFR1 pathway, TNF-α is an upstream ligand; however, TECs insufficiently transmit downstream effectors for lymphocyte infiltration. There may be several possible causes: 1) a deficient TNF-α supply in the tumor microenvironment of PDAC, 2) TNFR downregulation on TECs, or 3) abrogated downstream signaling in TECs. Higher TNF-α levels have been reported in PDAC patients than in healthy individuals. For TNFR downregulation on TECs, there were no significant differences in the TNFR expression levels between the endothelial cells from the noncancerous pancreas and TECs in our experiment (data not shown). Therefore, we focused on abrogated downstream signaling in TECs.

In general, IAPs are a family of proteins consisting of cIAP1, cIAP2, and XIAP, which inhibit apoptosis by blocking caspase activation or activity in the TNFR1 signaling pathway, through limiting non-canonical NF-κB signaling, promoting canonical
NF-κB and mitogen-activated protein kinase (MAPK) signaling, and inhibiting both caspase-dependent and -independent cell death.\textsuperscript{27} IAPs can also regulate innate immune responses and the Toll-like receptor signaling pathways,\textsuperscript{27} although the regulation is not simple as the regulatory roles are different among members of IAPs and cell types. Also, XIAP has an essential role in nucleotide-binding oligomerization domain (NOD) signaling, connected from cellular recognition of bacterial peptidoglycan derivatives through NOD1/2, leading to the production of inflammatory mediators. XIAP-deficient patients and animals are affected by a range of immunological defects, including hemophagocytic lymphohistiocytosis and inflammatory bowel disease like Crohn’s disease.\textsuperscript{28,29} In endothelial cells, IAPs are crucial regulators of vascular integrity, survival, angiogenesis, and homeostasis.\textsuperscript{30} Specifically, cIAP1 and cIAP2 regulate the activation of downstream signaling, that is, NF-κB signaling.\textsuperscript{31} XIAP also participates in the NF-κB activation cascade,\textsuperscript{32} which may lead to enhanced migration and adhesion of physiologically normal endothelial cells.\textsuperscript{33} Thus, IAPs and their subfamily molecules are associated with endothelial function, although the details of their roles in the molecular pathway remain to be elucidated. In this study, we observed increased adhesion and transmigration behavior between lymphocytes and TECs via VCAM-1 upregulation induced by the addition of an XIAP inhibitor. These changes may be caused by unique intracellular signaling cascades or crosstalk among TECs, as shown in this study. At least in part, inhibiting XIAP may contribute to the vascular normalization by TECs for inducing lymphocyte extravasation. Further mechanistic studies are needed to understand the endothelial functional alterations in TECs that become more profound during treatment.

Recently, studies targeting IAPs for cancer treatment have been actively performed, in which IAP inhibitors have been used for the induction of tumor cell death.\textsuperscript{34–36} Targeting all three IAPs is highly inflammatory and dead tumor cells can help trigger the immune system to attack cancer cells. Such events allow the enhance the antitumor effect.\textsuperscript{34–36} Indeed, IAP inhibitors can increase the production of death ligands, IFNγ, and IL-2 by immune cells, sensitizing cancer cells to the death ligands produced, enhancing cytotoxic lymphocyte killing of tumor cells, and reducing immune suppressive T cell functions.\textsuperscript{37–41} Thus, vascular normalization activity, a new additional activity of IAP inhibitors found in this study, will provide an excellent tool for developing a combination therapy.

Recovering the dysfunctional TECs by Embelin occurred at a lower concentration compared to that of the tumor-cell-killing effect. Embelin has been shown to have an antitumor effect on glioma, leukemia, and pancreatic cancers in \textit{in vitro} assays using cell lines\textsuperscript{23–24} where more than 20–30 μM of Embelin was needed in contrast to the 0.1 μM concentration required for inducing the lymphocyte-trafficking-related adhesion molecules in TECs, as shown in this study. Although Embelin was used at a relatively low dose to avoid its direct tumor-killing effect in the animal model in this study, if a high dose of Embelin is administered, higher antitumor activity is expected through direct tumor killing, vascular normalization, and some additional immunological effects, as described above.

Other than PDAC, some colorectal cancer, non-small cell lung cancer, and squamous cell carcinoma of the head and neck are also immune-quiescent ‘cold’ tumors.\textsuperscript{4,6} Our methodology may be similarly applicable to these immunologically quiescent tumors and could identify a compound to reprogram TECs for a successful antitumor response. Although many immunotherapeutic modalities, such as cancer vaccines, activated autologous lymphocyte therapies, checkpoint inhibitors, and genetically engineered T cells, have been developed in the past decade to halt PDAC progression, some previous attempts have not resulted in beneficial clinical outcomes for unknown reasons.\textsuperscript{4–6} Here, we suggest that these failures were due in part to not considering lymphocyte-TEC interactions and propose a novel modality of combination therapy. Combination therapy targeting TECs could be essential for improving immunotherapy efficacy and should be considered in future clinical trials. Otherwise, immunotherapies that do not consider TECs could fail in clinical trials.

In conclusion, our strategy may be added to the therapeutic arsenal for treating the immune-quiescent tumor microenvironment to produce a beneficial immune response.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

The authors thank Ms. Sachiko Miura, Toshiko Sakaguchi, and Chizu Kina for excellent techniques. We are grateful to the National Cancer Center Biobank for the tissue samples used in this study.

**Funding**

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, #18K07008 (NH) and #18K16377 (KN), and the Japan Agency for Medical Research and Development, #17H05801 (NH).

**References**

1. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014–1022.
2. Nakajima K, Nangia-Makker P, Hogan V, Raz A. Cancer self-defense: an immune stealth. Cancer Res. 2017;77:5441–5444. doi:10.1158/0008-5472.CAN-17-1324.
3. Salmon H, Remark R, Gnjatic S, Merad M. Host tissue determinants of tumour immunity. Nat Rev Cancer. 2019;19:215–227.
4. Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156:2056–2072. doi:10.1053/j.gastro.2018.12.038.
5. Foley K, Kim V, Jaffee E, Zheng L. Current progress in immunotherapy for pancreatic cancer. Cancer Lett. 2016;381:244–251. doi:10.1016/j.canlet.2015.12.020.
6. Xu JW, Wang L, Cheng YG, Zhang GY, Hu SY, Zhou B, Zhan H-X. Immunotherapy for pancreatic cancer: A long and hopeful journey. Cancer Lett. 2018;425:143–151. doi:10.1016/j.canlet.2018.03.040.
7. Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N. Immune cell infiltration as an indicator of
the immune microenvironment of pancreatic cancer. Br J Cancer. 2013;108(4):914–923. doi:10.1038/bjc.2013.32.

Hiraoka N, Ino Y, Yamazaki-Itoh R, Kanai Y, Kosuge T, Shimada K. Intratumoral tertiary lymphoid organ is a favourable prognostic indicator in patients with pancreatic cancer. Br J Cancer. 1978;92;2015:112.

Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune suppression. Nat Med. 2008;14(1):28–36. doi:10.1038/nm1699.

Shetty S, Weston CJ, Oo YH, Westerlund N, Stamataki Z, Youster J, Hubscher SG, Salmi M, Jalkanen S, Lator PF, et al. Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium. J Immunol. 2011;186(7):4147–4155. doi:10.4049/jimmunol.1002961.

Motz GT, Santoro SP, Wang LP, Garrabrant T, Lstra RR, Hagemann IS, Lai P, Feldman MD, Benencia F, Coukos G, et al. Tumor endothelium Fasl establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–615. doi:10.1038/nm.3541.

Brierley JD, Gospodarowicz MK, Wittkind C. TNM classification of malignant tumours. Hoboken (NJ): Wiley-Blackwell; 2017.

Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology. 2011;140:310–321. doi:10.1053/j.gastro.2010.10.009.

Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrad TS, Veenstra TD, Hitt BA, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437–450. doi:10.1016/S1535-6108(03)00309-X.

Friedl P, Weigel M. Interstitial leukocyte migration and immune function. Nat Immunol. 2008;9:960–969.

Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol. 2005;6:1182–1190. doi:10.1038/nili727.

Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60–66. doi:10.1126/science.272.5258.60.

Hiraoka N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol. 2010;15:544–551.

Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007;7:803–815.

Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol. 2003;3:745–756.

Dejana E. Endothelial cell-cell junctions: happy together. Nat Rev Mol Cell Biol. 2004;5:261–270. doi:10.1038/nrm1357.

Siegelin MD, Gaiser T, Siegelin Y. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP. Neurochem Int. 2009;55:423–430. doi:10.1016/j.neuint.2009.04.011.

Hu R, Zhu K, Li Y, Yao K, Zhang R, Wang H, Yang W, Liu Z. Embelin induces apoptosis through down-regulation of XIAP in human leukemia cells. Med Oncol. 2011;28:1584–1588. doi:10.1007/s12032-010-9601-5.

Peng M, Huang B, Zhang Q, Fu S, Wang D, Cheng X, Wu X, Xue Z, Zhang L, Zhang D, et al. Embelin inhibits pancreatic cancer progression by directly inducing cancer cell apoptosis and indirectly restricting IL-6 associated inflammatory and immune suppressive cells. Cancer Lett. 2014;345:407–416. doi:10.1016/j.canlet.2014.08.011.

Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity. 2014;41:694–707. doi:10.1016/j.immuni.2014.10.008.

Błogowski W, Deskur A, Budkowska M, Salata D, Madej-Michniewicz A, Dabkowskii K, Dołęgowska B, Starzyńska T, Selected cytokines in patients with pancreatic cancer: a preliminary report. PLoS One. 2014;9:e97613. doi:10.1371/journ.

Lalaouli NV, D.L. Recent advances in understanding inhibitor of apoptosis proteins. F1000 Faculty Rev. 2019;7:1889.

Bauler LD, Dukett CS, O’Riordan MX. XIAP regulates cytosol-specific innate immunity to Listeria infection. PLoS Pathog. 2008;4:e1000142.

Latour S, Aguilar C. XIAP deficiency syndrome in humans. Semin Cell Dev Biol. 2015;39:115–123. doi:10.1016/j.scbem.2015.01.015.

Santoro MM, Samuel T, Mitchell T, Reed JC, Stainer DY. Birc2 (clap1) regulates endothelial cell integrity and blood vessel homeostasis. Nat Genet. 2007;39:1397–1402. doi:10.1038/ng.2007.8.

Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enware E, Ver W, Mak TW, Lacasse EC, Waring J, et al. Both clap1 and clap2 regulate TNFα-mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 2008;105:11778–11783. doi:10.1073/pnas.0711122105.

Hofer-Warbinek R, Schmid JA, Stehlík C, Binder BR, Lipp J, de Martin R. Activation of XIAP and FADD by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J Biol Chem. 2000;275:22064–22068.

Kline J, Ahn S, Ko YG, Boo YC, Chi SG, Ni CW, Go YM, Jo H, Park H. X-linked inhibitor of apoptosis protein controls alpha5-integrin-mediated cell adhesion and migration. Am J Physiol Heart Circ Physiol. 2010;299:H300–9. doi:10.1152/ajpheart.00180.2010.

Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol. 2014;32(2):182–190. doi:10.1038/nb.2806.

Brumatti G, Ma C, Lalaouli N, Nguyen NY, Navarro M, Tanzer MC, Richmond J, Ghisi M, Salmon JM, Silke N, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birkinnap to induce necroptosis and treat acute myeloid leukemia. Sci Trans Med. 2016;8:333ra69.

Lalaouli N, Hanggi K, Brumatti G, Chau D, Nguyen NY, Vassilkos L, Spiliges L, Heckmann D, Ma C, Ghisi M, et al. Targeting p38 or MK2 enhances the anti-leukemic activity of smac-mimetics. Cancer Cell. 2016;29(2):145–158. doi:10.1016/j.ccell.2016.01.006.

Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcino L, Brigg DL, et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016;22(12):1411–1420. doi:10.1038/nm.4229.

Clancy-Thompson E, Ali L, Bruck PT, Exley MA, Blumberg RS, Dronoff G, Dougan SK. IAP antagonists enhance cytokine production from mouse and human NK/T cells. Cancer Immunol Res. 2018;6:25–35.

Dougan M, Dougan S, Sliz J, Firestone B, Vanneman M, Dragovan D, Goyal G, Li W, Neuberg D, Blumberg R, et al. IAP inhibitors enhance co-stimulation to promote tumor immunity. J Exp Med. 2010;207(10):2195–2206. doi:10.1084/jem.20101123.

Kim DS, Dasitdar H, Zhang C, Zemp FJ, Lau K, Ernst M, Rakic A, Sikdar S, Rajwani J, Naumenko V, et al. Smac mimetics and oncolytic viruses synergize in driving anticaner T-cell responses through complementary mechanisms. Nat Commun. 2017;8:344. doi:10.1038/s41467-017-00324-x.

Xiao R, Allen CT, Tran L, Patel P, Park SJ, Chen Z, Van Waes C, Schmitt NC. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer. Oncoimmunology. 2018;7:e1471440. doi:10.1080/